Online ISSN: 1949-2553
www.oncotarget.com
About Oncotarget
Our mission is to make scientific results rapidly and widely available. We seek to maximize the impact of research via insightful review, to enable exceptional discoveries to be shared quickly, to eliminate the border between specialties, to link different fields of biomedical science, and to foster application of basic and clinical science to fight disease.

LEARN MORE ABOUT ONCOTARGET

“From Osimertinib to Preemptive Combinations” by Dr. Blagosklonny

News

March 19, 2024
PRESS RELEASE: On March 15, 2024, a new research perspective was published by Mikhail V. Blagosklonny M.D., Ph.D., in Oncotarget, entitled, “From osimertinib to preemptive combinations.” continue reading »

A New Antibody Capture Method Reveals G-quadruplex Landscape and its Regulation

News

March 18, 2024
PRESS RELEASE: On March 14, 2024, a new research paper was published in Oncotarget, entitled, “G-quadruplex landscape and its regulation revealed by a new antibody capture method.” continue reading »

Antitumor Effects of Sacituzumab Govitecan Plus Platinum-Based Chemotherapy

Oncotarget

March 14, 2024
In this study, researchers investigated the antitumor effects of Sacituzumab govitecan in combination with platinum-based chemotherapy. continue reading »

GZ17-6.02 With Proteasome Inhibitors Kills Multiple Myeloma Cells

News

March 6, 2024
PRESS RELEASE: On March 5, 2024, a new research paper was published in Oncotarget, entitled, “GZ17-6.02 interacts with proteasome inhibitors to kill multiple myeloma cells.” continue reading »

Sacituzumab Govitecan Plus Platinum-based Chemotherapy in Breast, Bladder, and Lung Carcinomas

News

March 4, 2024
PRESS RELEASE: On February 22, 2024, a new research paper was published in Oncotarget, entitled, “Sacituzumab govitecan plus platinum-based chemotherapy mediates significant antitumor effects in triple-negative breast, urinary bladder, and small-cell lung carcinomas.” continue reading »